Works about PHARMACEUTICAL policy

Results: 3082

Medical research without patents: It's preferable, it's profitable, and it's practicable.

Published in:

Accountability in Research: Policies & Quality Assurance, 2025, v. 32, n. 5, p. 785, doi. 10.1080/08989621.2024.2324913

By:

Radder, Hans;
Smiers, Joost

Publication type:

Article

What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, p. 36, doi. 10.1111/dom.16278

By:

Abitbol, A.;
Chu, L.

Publication type:

Article

The Journal of Generic Medicines – Editorial June 2025.

Published in:

2025

By:

Tempest, Brian

Publication type:

Editorial

An assessment of Canada's revised Patented Medicines (Notice of Compliance) Regulations.

Published in:

Journal of Generic Medicines, 2025, v. 21, n. 2, p. 52, doi. 10.1177/17411343251327092

By:

Hollis, Aidan

Publication type:

Article

A sex-sensitive LC-MS/MS method with isotopic internal standard for prazosin bioequivalence: bridging precision medicine and generic drug policy in China.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1592731

By:

Chen, Hui;
Guo, Junping;
Zhu, Zhenyu;
Huang, Xiaomei;
Guo, Jincai

Publication type:

Article

Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies.

Published in:

Pharmaceutical Medicine, 2025, v. 39, n. 3, p. 199, doi. 10.1007/s40290-025-00558-x

By:

Okada, Norihiro;
Takahashi, Yosuke

Publication type:

Article

Entre leis, moralidades e éticas: direitos humanos, usuário de drogas e política de redução de danos.

Published in:

Saúde e Sociedade, 2025, v. 34, n. 1, p. 1, doi. 10.1590/S0104-12902025240445pt

By:

Barreto Rodrigues, Luzania

Publication type:

Article

Beginning of an Educational Avalanche in Medicine Development and Regulation.

Published in:

Statistics in Biopharmaceutical Research, 2013, v. 5, n. 3, p. 259, doi. 10.1080/19466315.2013.817353

By:

Bühler, Fritz

Publication type:

Article

Emergency Use Authorization for COVID-19 Polymerase Chain Reaction Kits: A Confusing Continuation.

Published in:

Archives of Pathology & Laboratory Medicine, 2025, v. 149, n. 6, p. 496, doi. 10.5858/arpa.2024-0506-LE

By:

Waisberg, Michael

Publication type:

Article

Expanded access to intranasal naloxone and training among police officers in Western Australia: A pilot evaluation study.

Published in:

Drug & Alcohol Review, 2025, v. 44, n. 4, p. 1114, doi. 10.1111/dar.14032

By:

Agramunt, Seraina;
Lenton, Simon

Publication type:

Article

New Drug Application Filed for Pixantrone.

Published in:: Oncology (08909091), 2009, v. 23, n. 10, p. 825
Publication type:: Article

FDA Issues Final Rules to Help Patients Gain Access to Investigational Drugs.

Published in:: Oncology (08909091), 2009, v. 23, n. 10, p. 814
Publication type:: Article

FDA Extends Review of Ofatumumab.

Published in:: Oncology (08909091), 2009, v. 23, n. 10, p. 810
Publication type:: Article

Vectibix Approved for Advanced Colorectal Cancer.

Published in:: Oncology (08909091), 2006, v. 20, n. 11, p. 1451
Publication type:: Article

Noxafil Approved for Prevention of Invasive Aspergillus Infections.

Published in:: Oncology (08909091), 2006, v. 20, n. 11, p. 1451
Publication type:: Article

FDA Guidances for Early Human Testing of New Drugs.

Published in:: Oncology (08909091), 2006, v. 20, n. 4, p. 325
Publication type:: Article

NCI Supports Interagency Oncology Task Force Efforts to Develop Faster, Safer Interventions.

Published in:: Oncology (08909091), 2006, v. 20, n. 3, p. 216
Publication type:: Article

FDA Approves Erlotinib/Gemeitabine to Treat Advanced Pancreatic Cancer.

Published in:: Oncology (08909091), 2005, v. 19, n. 14, p. 1842
Publication type:: Article

Capecitabine Approved for Adjuvant Treatment of Colon Cancer.

Published in:: Oncology (08909091), 2005, v. 19, n. 8, p. 1072
Publication type:: Article

Tenders for generics and biosimilars: a challenging purchasing policy.

Published in:

European Journal of Health Economics, 2023, v. 24, n. 4, p. 485, doi. 10.1007/s10198-023-01580-z

By:

Antoñanzas, Fernando;
Juárez-Castelló, Carmelo;
Rodríguez-Ibeas, Roberto

Publication type:

Article

Does external reference pricing deliver what it promises? Evidence on its impact at national level.

Published in:

2020

By:

Kanavos, Panos;
Fontrier, Anna-Maria;
Gill, Jennifer;
Efthymiadou, Olina

Publication type:

journal article

Modest risk-sharing significantly reduces health plans' incentives for service distortion.

Published in:

2019

By:

Brammli-Greenberg, Shuli;
Glazer, Jacob;
Waitzberg, Ruth

Publication type:

journal article

Variations in external reference pricing implementation: does it matter for public policy?

Published in:

2019

By:

Gill, Jennifer;
Fontrier, Anna-Maria;
Kyriopoulos, Dionysis;
Kanavos, Panos

Publication type:

journal article

International impact of external reference pricing: should national policy-makers care?

Published in:

2019

By:

Fontrier, Anna-Maria;
Gill, Jennifer;
Kanavos, Panos

Publication type:

journal article

Market approval for drugs in the EU: time to change direction?

Published in:

2017

By:

Curto, Alessandro;
de Vooren, Katelijne;
Garattini, Livio;
van de Vooren, Katelijne

Publication type:

Editorial

Examining the determinants of drug launch delay in pre-TRIPS India.

Published in:

European Journal of Health Economics, 2013, v. 14, n. 5, p. 761, doi. 10.1007/s10198-012-0422-7

By:

Bhaduri, Saradindu;
Brenner, Thomas

Publication type:

Article

Separating the wheat from the chaff.

Published in:

2012

By:

Runge, Claus

Publication type:

Editorial

Do you believe in magic? Improving the quality of pharmacy services through restricting entry and aspirational contracts, the Irish experience.

Published in:

European Journal of Health Economics, 2011, v. 12, n. 6, p. 521, doi. 10.1007/s10198-010-0264-0

By:

Gorecki, Paul

Publication type:

Article

The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.

Published in:

European Journal of Health Economics, 2011, v. 12, n. 6, p. 563, doi. 10.1007/s10198-010-0271-1

By:

Moreno-Torres, Iván;
Puig-Junoy, Jaume;
Raya, Josep

Publication type:

Article

Pharmaceutical pricing and reimbursement reforms in Greece.

Published in:

European Journal of Health Economics, 2008, v. 9, n. 1, p. 87, doi. 10.1007/s10198-007-0061-6

By:

Yfantopoulos, John

Publication type:

Article

Pharmaceutical policy in Italy.

Published in:

2006

By:

Garattini, Livio;
Cornago, Dante

Publication type:

Editorial

The high cost of medicines in Ireland.

Published in:

European Journal of Health Economics, 2004, v. 5, n. 4, p. 341, doi. 10.1007/s10198-004-0245-2

By:

Tilson, Lesley;
McGowan, Bernadette;
Bennett, Kathleen;
Barry, Michael

Publication type:

Article

Out-patient drug policy by clinical assessment rather than financial constraints?

Published in:

European Journal of Health Economics, 2004, v. 5, n. 3, p. 274, doi. 10.1007/s10198-003-0223-0

By:

Pronk, Marja H.;
Bonsel, Gouke J.

Publication type:

Article

Pricing and reimbursement of drugs in Ireland.

Published in:

European Journal of Health Economics, 2004, v. 5, n. 2, p. 190, doi. 10.1007/s10198-004-0225-6

By:

Barry, Michael;
Tilson, Lesley;
Ryan, M&aaacute;rín

Publication type:

Article

An overview of the Greek pharmaceutical market.

Published in:

European Journal of Health Economics, 2003, v. 4, n. 4, p. 327, doi. 10.1007/s10198-003-0206-1

By:

Kontozamanis, V.;
Mantzouneas, E.;
Stoforos, C.

Publication type:

Article

What criteria for pharmaceuticals reimbursement? : An empirical analysis of the evaluation of “medical service rendered” by reimbursable drugs in France.

Published in:

European Journal of Health Economics, 2003, v. 4, n. 1, p. 30, doi. 10.1007/s10198-002-0145-2

By:

Le Pen, C.;
Priol, G.;
Lilliu, H.

Publication type:

Article

Pricing and reimbursement of drugs in Denmark.

Published in:

European Journal of Health Economics, 2003, v. 4, n. 1, p. 60, doi. 10.1007/s10198-003-0165-6

By:

Pedersen, K. Møller

Publication type:

Article

Pricing and reimbursement of pharmaceuticals in Norway.

Published in:

European Journal of Health Economics, 2002, v. 3, n. 3, p. 215, doi. 10.1007/s10198-002-0135-4

By:

Hågå, A.;
Sverre, J. M.

Publication type:

Article

The pricing of pharmaceuticals in low-income countries.

Published in:

European Journal of Health Economics, 2002, v. 3, n. 4, p. 223, doi. 10.1007/s10198-002-0151-4

By:

Rovira, J.

Publication type:

Article

Pricing and reimbursement of drugs and medical devices in Hungary.

Published in:

European Journal of Health Economics, 2002, v. 3, n. 4, p. 271, doi. 10.1007/s10198-002-0148-z

By:

Gulácsi, L.;
Dávid, T.;
Dózsa, Cs.

Publication type:

Article

Pricing and reimbursement of pharmaceuticals in Portugal.

Published in:

European Journal of Health Economics, 2002, v. 3, n. 4, p. 267, doi. 10.1007/s10198-002-0146-1

By:

Gouveia Pinto, C.;
Teixeira, I.

Publication type:

Article

Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review.

Published in:

PLoS Medicine, 2011, v. 8, n. 5, p. 1, doi. 10.1371/journal.pmed.1001037

By:

Austad, Kirsten E.;
Avorn, Jerry;
Kesselheim, Aaron S.

Publication type:

Article

Registering New Drugs for Low-Income Countries: The African Challenge.

Published in:

PLoS Medicine, 2011, v. 8, n. 2, p. 1, doi. 10.1371/journal.pmed.1000411

By:

Moran, Mary;
Strub-Wourgaft, Nathalie;
Guzman, Javier;
Boulet, Pascale;
Wu, Lindsey;
Pecoul, Bernard

Publication type:

Article

Are Drug Companies Living Up to Their Human Rights Responsibilities? The Merck Perspective.

Published in:

PLoS Medicine, 2010, v. 7, n. 9, p. 1, doi. 10.1371/journal.pmed.1000343

By:

Ritter, Geralyn S.

Publication type:

Article

Off-Label Promotion, On-Target Sales.

Published in:

PLoS Medicine, 2008, v. 5, n. 10, p. 1432, doi. 10.1371/journal.pmed.0050210

By:

Fugh-Berman, Adriane;
Melnick, Douglas

Publication type:

Article

Disease mongering in drug promotion: do governments have a regulatory role?

Published in:

2006

By:

Mintzes, Barbara

Publication type:

journal article

What are the public health effects of direct-to-consumer drug advertising?

Published in:

2006

By:

Almasi, Elizabeth A.;
Stafford, Randall S.;
Kravitz, Richard L.;
Mansfield, Peter R.

Publication type:

journal article

The FDA ban of L-tryptophan: Politics, profits and Prozac.

Published in:

Social Policy, 1995, v. 26, n. 2, p. 55

By:

Manders, Wolfe

Publication type:

Article

They Work in Mysterious Ways.

Published in:

Social Alternatives, 2002, v. 21, n. 1, p. 56

By:

Smith, Debra

Publication type:

Article

Stains recently certified.

Published in:: Biotechnic & Histochemistry, 2008, v. 83, n. 5, p. 259, doi. 10.1080/10520290802560240
Publication type:: Article